Philippines Health News API

{
    "totalArticles": 107640,
    "articles": [
        {
            "id": "2a300514fc07d9edb39e7653adbc9524",
            "title": "ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer",
            "description": "The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.",
            "content": "At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was presented at the plenary session.\nAt an 8.5-month follow-up all primary and secondary endpoints were met. Previously treated me... [2461 chars]",
            "url": "https://www.clinicaltrialsarena.com/analyst-comment/asco26-revmeds-daraxonrasib-presents-a-turning-point-for-pancreatic-cancer/",
            "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2026/06/shutterstock_2131663599.jpg",
            "publishedAt": "2026-06-02T10:14:20Z",
            "lang": "en",
            "source": {
                "id": "5fc6401b64c5c4ee117332a7a598b722",
                "name": "Clinical Trials Arena",
                "url": "https://www.clinicaltrialsarena.com"
            }
        },
        {
            "id": "518a30e2a8dd736e648467c563886d15",
            "title": "WHO chief ends DR Congo visit as group warns Ebola likely spread undetected",
            "description": "Tedros meets President Tshisekedi amid warnings that four out of five virus contacts have gone untraced.",
            "content": "The head of the World Health Organization on Monday concluded his visit to Democratic Republic of Congo by briefing the president on the response to the Ebola outbreak, which an aid agency warned was likely much larger than official figures show.\nThe... [852 chars]",
            "url": "https://www.scmp.com/news/world/africa/article/3355662/who-chief-ends-dr-congo-visit-group-warns-ebola-likely-spread-undetected",
            "image": "https://cdn.i-scmp.com/sites/default/files/styles/og_image_scmp_generic/public/d8/images/canvas/2026/06/02/20adad50-3d82-4e7f-96ab-6f15722a02c4_7426b3cc.jpg?itok=1Cxf_yzj&v=1780382233",
            "publishedAt": "2026-06-02T06:37:14Z",
            "lang": "en",
            "source": {
                "id": "9709bfa71bc46e81262e4096f206f257",
                "name": "South China Morning Post",
                "url": "https://www.scmp.com"
            }
        },
        {
            "id": "d08e48b3a304175052b8d879f7b27ac7",
            "title": "Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types",
            "description": "Data from Phase 1b EMITT-1 trial presented in oral session at ASCO 2026 Annual Meeting",
            "content": "Data from Phase 1b EMITT-1 trial presented in oral session at ASCO 2026 Annual Meeting\nFirst-in-class oral ERAP1 inhibitor demonstrates objective response rates (ORR) of 13-36% across patients with secondary anti-PD-1 resistance or microsatellite sta... [5707 chars]",
            "url": "https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/greywolf-therapeutics-reports-durable-clinical-responses-with-first-in-class-oral-erap1-inhibitor-grwd5769-across-six-solid-tumor-types/2356452",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/06/02/1081408.png",
            "publishedAt": "2026-06-02T06:16:47Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        }
    ]
}